Wang SK, et al. - In view of the observation that ethnic minorities (nonwhites) with critical limb ischemia (CLI) have historically performed worse compared with whites with regard to major amputation risk reduction and amputation-free survival (AFS) after peripheral vascular intervention, researchers here investigated if this precedent also extended to treatment of CLI without a suitable revascularization option with intramuscular injections of concentrated bone marrow aspirate (cBMA). Findings demonstrated noninferiority of cBMA intervention for the therapeutic end point of major amputation prevention in minorities with no-option CLI. Thereby suggesting that for minorities with poor revascularization options who face impending amputation secondary to progressive CLI, cBMA represented a novel treatment paradigm.